Abstract
Comprehensive multiplatform analysis of 80 uveal melanomas (UM) identifies four molecularly distinct, clinically relevant subtypes: two associated with poor-prognosis monosomy 3 (M3) and two with better-prognosis disomy 3 (D3). We show that BAP1 loss follows M3 occurrence and correlates with a global DNA methylation state that is distinct from D3-UM. Poor-prognosis M3-UM divide into subsets with divergent genomic aberrations, transcriptional features, and clinical outcomes. We report change-of-function SRSF2 mutations. Within D3-UM, EIF1AX- and SRSF2/SF3B1-mutant tumors have distinct somatic copy number alterations and DNA methylation profiles, providing insight into the biology of these low- versus intermediate-risk clinical mutation subtypes.
Original language | English |
---|---|
Pages (from-to) | 204-220.e15 |
Journal | Cancer Cell |
Volume | 32 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2017 Aug 14 |
Externally published | Yes |
Keywords
- EIF1AX
- GNA11
- GNAQ
- SF3B1
- SRSF2
- TCGA
- molecular subtypes
- monosomy 3
- noncoding RNA
- uveal melanoma
ASJC Scopus subject areas
- Oncology
- Cancer Research
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Cancer Cell, Vol. 32, No. 2, 14.08.2017, p. 204-220.e15.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma
AU - Robertson, A. Gordon
AU - Shih, Juliann
AU - Yau, Christina
AU - Gibb, Ewan A.
AU - Oba, Junna
AU - Mungall, Karen L.
AU - Hess, Julian M.
AU - Uzunangelov, Vladislav
AU - Walter, Vonn
AU - Danilova, Ludmila
AU - Lichtenberg, Tara M.
AU - Kucherlapati, Melanie
AU - Kimes, Patrick K.
AU - Tang, Ming
AU - Penson, Alexander
AU - Babur, Ozgun
AU - Akbani, Rehan
AU - Bristow, Christopher A.
AU - Hoadley, Katherine A.
AU - Iype, Lisa
AU - Chang, Matthew T.
AU - Abdel-Rahman, Mohamed H.
AU - Ally, Adrian
AU - Auman, J. Todd
AU - Balasundaram, Miruna
AU - Balu, Saianand
AU - Benz, Christopher
AU - Beroukhim, Rameen
AU - Birol, Inanc
AU - Bodenheimer, Tom
AU - Bowen, Jay
AU - Bowlby, Reanne
AU - Brooks, Denise
AU - Carlsen, Rebecca
AU - Cebulla, Colleen M.
AU - Cherniack, Andrew D.
AU - Chin, Lynda
AU - Cho, Juok
AU - Chuah, Eric
AU - Chudamani, Sudha
AU - Cibulskis, Carrie
AU - Cibulskis, Kristian
AU - Cope, Leslie
AU - Coupland, Sarah E.
AU - Defreitas, Timothy
AU - Demchok, John A.
AU - Desjardins, Laurence
AU - Dhalla, Noreen
AU - Esmaeli, Bita
AU - Felau, Ina
AU - Ferguson, Martin L.
AU - Frazer, Scott
AU - Gabriel, Stacey B.
AU - Gastier-Foster, Julie M.
AU - Gehlenborg, Nils
AU - Gerken, Mark
AU - Gershenwald, Jeffrey E.
AU - Getz, Gad
AU - Griewank, Klaus G.
AU - Grimm, Elizabeth A.
AU - Hayes, D. Neil
AU - Hegde, Apurva M.
AU - Heiman, David I.
AU - Helsel, Carmen
AU - Hobensack, Shital
AU - Holt, Robert A.
AU - Hoyle, Alan P.
AU - Hu, Xin
AU - Hutter, Carolyn M.
AU - Jager, Martine J.
AU - Jefferys, Stuart R.
AU - Jones, Corbin D.
AU - Jones, Steven J.M.
AU - Kandoth, Cyriac
AU - Kasaian, Katayoon
AU - Kim, Jaegil
AU - Kucherlapati, Raju
AU - Lander, Eric
AU - Lawrence, Michael S.
AU - Lazar, Alexander J.
AU - Lee, Semin
AU - Leraas, Kristen M.
AU - Lin, Pei
AU - Liu, Jia
AU - Liu, Wenbin
AU - Lolla, Laxmi
AU - Lu, Yiling
AU - Ma, Yussanne
AU - Mahadeshwar, Harshad S.
AU - Mariani, Odette
AU - Marra, Marco A.
AU - Mayo, Michael
AU - Meier, Sam
AU - Meng, Shaowu
AU - Meyerson, Matthew
AU - Mieczkowski, Piotr A.
AU - Mills, Gordon B.
AU - Moore, Richard A.
AU - Mose, Lisle E.
AU - Mungall, Andrew J.
AU - Murray, Bradley A.
AU - Naresh, Rashi
AU - Noble, Michael S.
AU - Pantazi, Angeliki
AU - Parfenov, Michael
AU - Park, Peter J.
AU - Parker, Joel S.
AU - Perou, Charles M.
AU - Pihl, Todd
AU - Pilarski, Robert
AU - Protopopov, Alexei
AU - Radenbaugh, Amie
AU - Rai, Karan
AU - Ramirez, Nilsa C.
AU - Ren, Xiaojia
AU - Reynolds, Sheila M.
AU - Roach, Jeffrey
AU - Roman-Roman, Sergio
AU - Roszik, Jason
AU - Sadeghi, Sara
AU - Saksena, Gordon
AU - Sastre, Xavier
AU - Schadendorf, Dirk
AU - Schein, Jacqueline E.
AU - Schoenfield, Lynn
AU - Schumacher, Steven E.
AU - Seidman, Jonathan
AU - Seth, Sahil
AU - Sethi, Geetika
AU - Sheth, Margi
AU - Shi, Yan
AU - Shields, Carol
AU - Shmulevich, Ilya
AU - Simons, Janae V.
AU - Singh, Arun D.
AU - Sipahimalani, Payal
AU - Skelly, Tara
AU - Sofia, Heidi
AU - Soloway, Matthew G.
AU - Song, Xingzhi
AU - Stern, Marc Henri
AU - Stuart, Joshua
AU - Sun, Qiang
AU - Sun, Huandong
AU - Tam, Angela
AU - Tan, Donghui
AU - Tang, Jiabin
AU - Tarnuzzer, Roy
AU - Taylor, Barry S.
AU - Thiessen, Nina
AU - Thorsson, Vesteinn
AU - Tse, Kane
AU - Veluvolu, Umadevi
AU - Verhaak, Roel G.W.
AU - Voet, Doug
AU - Wan, Yunhu
AU - Wang, Zhining
AU - Weinstein, John N.
AU - Wilkerson, Matthew D.
AU - Williams, Michelle D.
AU - Wise, Lisa
AU - Woodman, Scott E.
AU - Wong, Tina
AU - Wu, Ye
AU - Yang, Liming
AU - Yang, Lixing
AU - Zenklusen, Jean C.
AU - Zhang, Jiashan
AU - Zhang, Hailei
AU - Zmuda, Erik
N1 - Funding Information: We are grateful to all patients and families who contributed to this study. We thank Dr. Jasmine Francis, Dr. Amy Schefler and Dr Helen Kalirai for following through with the requirements for sample submission. This work was supported by the following grants from the NIH: U54 HG003273, U54 HG003067, U54 HG003079, U24 CA143799, U24 CA143835, U24 CA143840, U24 CA143843, U24 CA143845, U24 CA143848, U24 CA143858, U24 CA143866, U24 CA143867, U24 CA143882, U24 CA143883, U24 CA144025, P30 CA016672, P50 CA083639, and K08 EY022672 (C.M.C.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. E.A.G. is an employee of GenomeDx Biosciences. A.D.C. declares research funding from Bayer AG. J.E.G. has an advisory role in Castle Biosciences and Merck. K.G.G. holds the patent for WO2011130691: GNA11 and GNAQ exon 4 mutations in melanoma. Publisher Copyright: © 2017 The Authors
PY - 2017/8/14
Y1 - 2017/8/14
N2 - Comprehensive multiplatform analysis of 80 uveal melanomas (UM) identifies four molecularly distinct, clinically relevant subtypes: two associated with poor-prognosis monosomy 3 (M3) and two with better-prognosis disomy 3 (D3). We show that BAP1 loss follows M3 occurrence and correlates with a global DNA methylation state that is distinct from D3-UM. Poor-prognosis M3-UM divide into subsets with divergent genomic aberrations, transcriptional features, and clinical outcomes. We report change-of-function SRSF2 mutations. Within D3-UM, EIF1AX- and SRSF2/SF3B1-mutant tumors have distinct somatic copy number alterations and DNA methylation profiles, providing insight into the biology of these low- versus intermediate-risk clinical mutation subtypes.
AB - Comprehensive multiplatform analysis of 80 uveal melanomas (UM) identifies four molecularly distinct, clinically relevant subtypes: two associated with poor-prognosis monosomy 3 (M3) and two with better-prognosis disomy 3 (D3). We show that BAP1 loss follows M3 occurrence and correlates with a global DNA methylation state that is distinct from D3-UM. Poor-prognosis M3-UM divide into subsets with divergent genomic aberrations, transcriptional features, and clinical outcomes. We report change-of-function SRSF2 mutations. Within D3-UM, EIF1AX- and SRSF2/SF3B1-mutant tumors have distinct somatic copy number alterations and DNA methylation profiles, providing insight into the biology of these low- versus intermediate-risk clinical mutation subtypes.
KW - EIF1AX
KW - GNA11
KW - GNAQ
KW - SF3B1
KW - SRSF2
KW - TCGA
KW - molecular subtypes
KW - monosomy 3
KW - noncoding RNA
KW - uveal melanoma
UR - http://www.scopus.com/inward/record.url?scp=85026887361&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026887361&partnerID=8YFLogxK
U2 - 10.1016/j.ccell.2017.07.003
DO - 10.1016/j.ccell.2017.07.003
M3 - Article
C2 - 28810145
AN - SCOPUS:85026887361
SN - 1535-6108
VL - 32
SP - 204-220.e15
JO - Cancer Cell
JF - Cancer Cell
IS - 2
ER -